Tag Archives: Pfizer

← Older posts Newer posts →

Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More

EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. But it offered few specifics about how it would achieve those goals. This week, drug licensing deals it made with two […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More

Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test

Moderna’s COVID-19 vaccine candidate stimulated production of antibodies to the novel coronavirus in all of the patients tested in an early-stage study, and the company says the data support the selection of which dose to test in a pivotal clinical trial slated to begin at the end of July. When the Cambridge, MA-based company initially […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, Europe top stories, National blog main, National top stories, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , | Comments Off on Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test

Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More

Cash flowed throughout the life sciences ecosystem this week as Blackstone (NYSE: BX) raised a record-setting life sciences fund, companies of all stages announced new financings, and money continued to find its way to those working on efforts to treat or prevent COVID-19. Financiers poured $100 million or more into at least three biotechs, a […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Europe blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Philadelphia Blog Main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More

CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

CSL Behring is joining the chase for a genetic treatment for hemophilia by acquiring a uniQure gene therapy that’s already in late-stage testing. King of Prussia, PA-based CSL Behring is paying $450 million up front to acquire the uniQure (NASDAQ: QURE) asset, etranacogene dezaparvovec (“EtranaDez” for short), the companies announced late Wednesday. Netherlands-based uniQure will […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, Philadelphia, Philadelphia Blog Main, Philadelphia Top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease

Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate. Headed by president and CEO Niall O’Donnell (pictured), the San Diego-based company launched last year […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine

Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test. The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: MRNA) announced Thursday. Those patients will be randomly assigned to receive either […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine

Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More

Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect the broad spectrum of patients that drug makers aim to treat. Racial disparities are […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More

Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders. The deal announced Monday covers the development of potential treatments for hemophilia, which stems from genetic mutations that lead to insufficient levels of blood clotting […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. Gene therapy company Generation […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq← Older posts Newer posts →